

Yi-Wen Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5769766/publications.pdf>

Version: 2024-02-01

8
papers

134
citations

1683354

5
h-index

1588620

8
g-index

8
all docs

8
docs citations

8
times ranked

200
citing authors

#	ARTICLE	IF	CITATIONS
1	The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 378-387.	1.1	64
2	Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. <i>Hepatology International</i> , 2021, 15, 1122-1135.	1.9	22
3	Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 61-69.	1.4	17
4	The burden and sexual dimorphism with nonalcoholic fatty liver disease in Asian children: A systematic review and meta-analysis. <i>Liver International</i> , 2022, 42, 1969-1980.	1.9	13
5	SHG/TPEF-based image technology improves liver fibrosis assessment of minimally sized needle biopsies. <i>Hepatology International</i> , 2019, 13, 501-509.	1.9	7
6	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , 2021, 41, 369-377.	1.9	4
7	Effect of breath holding at the end of the inspiration and expiration phases on liver stiffness measured by 2D-MR elastography. <i>Abdominal Radiology</i> , 2021, 46, 2516-2526.	1.0	4
8	Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy. <i>Hepatology International</i> , 2021, 15, 82-92.	1.9	3